Synthetic Methods

DOI: 10.1002/anie.200502779

The Chemical Synthesis of Bioactive Glycosylphosphatidylinositols from *Trypanosoma cruzi* Containing an Unsaturated Fatty Acid in the Lipid**

Dmitry V. Yashunsky, Vladimir S. Borodkin, Michael A. J. Ferguson, and Andrei V. Nikolaev*

Dedicated to Professor Nikolay K. Kochetkov on the occasion of his 90th birthday

Glycosylphosphatidylinositols (GPIs) are a class of natural glycosylphospholipids that anchor proteins and glycoproteins (through their C terminus) as well as phosphoglycans (through the reducing end of the chain) to the membrane of eukaryotic cells. Since the first full assignment of a GPI structure in 1988,^[1] a number of GPI anchors have been

 [*] Dr. D. V. Yashunsky, Dr. V. S. Borodkin, Dr. A. V. Nikolaev Faculty of Life Sciences Division of Biological Chemistry and Molecular Microbiology University of Dundee Carnelley Building, Dundee DD14HN (UK) Fax: (+44) 1382-386373 E-mail: a.v.nikolaev@dundee.ac.uk
Prof. M. A. J. Ferguson Faculty of Life Sciences Division of Biological Chemistry and Molecular Microbiology University of Dundee Wellcome Trust Building, Dundee DD15EH (UK)

- [**] This work, D.V.Y., and V.S.B. were supported by a Wellcome Trust Grant 067089/Z/02/Z. Prof. A. S. Shashkov (Moscow, Russia) is greatly acknowledged for NMR spectral characterization of the final compounds. We are grateful to Dr. A. Mehlert (Dundee) and Dr. V. Oleynikov (Moscow, Russia) for mass spectroscopic analyses and to Dr. A. J. Ross (Dundee) for the purification of compounds 1 and 2.
- Supporting information for this article is available on the WWW under http://www.angewandte.org or from the author.


characterized.^[2] The function of the compounds, in addition to the clear one of linking the above biopolymers to membranes, has been extensively discussed.^[2,3] There is also evidence that GPIs and/or their metabolites can act as secondary messengers, which modulate biological events including insulin production, insulin-mediated signal transduction, cellular proliferation, and cell–cell recognition. The discovered role as mediators of regulatory processes makes the chemical preparation of the compounds and their analogues of great interest. To date, a number of syntheses of GPIs (yeast,^[4] rat brain Thy-1,^[5] *Trypanosoma brucei*,^[6] *Leishmania*,^[7] *T. gondii*,^[8] *Plasmodium falciparum*,^[9] and *T. cruzi* 1G7 antigen^[10]) have been reported.

The protozoan parasite *Trypanosoma cruzi* is a causative agent of Chagas' disease, which affects about 18 million individuals in South and Central America.^[11] It is transmitted to mammals in the feces of a biting insect vector (hematophagous triatomine bug) and has four distinct developmental stages. Throughout the life cycle, *T. cruzi* produces both common and stage-specific GPI-anchored cell-surface macromolecules.^[12–15] Local release of GPI-anchored mucins by the bloodstream trypomastigote stage of the parasite is believed to be responsible for the development of parasite-elicited inflammation, which causes cardiac and other pathologies associated with the acute and chronic phases of Chagas' disease.^[15]

It has recently been discovered^[13] that a purified GPI fraction of T. cruzi trypomastigote mucins (trypomastigote GPI, or tGPI) revealed extraordinary proinflammatory activities, comparable to those of bacterial lipopolysaccharide. An ability to trigger the induction of tumor necrosis factor- α , interleukin-12, and nitric oxide at the 2–30 pM level (when presented to macrophages) showed that tGPI is one of the most potent microbial proinflammatory agents known. The structure of the cytokine- and NO-inducing tGPI anchor has been defined,^[13] and the extreme biological activity was allegedly associated with the presence of unsaturated fatty acids in the sn^2 position of the alkylacylglycerophosphate moiety^[*] (1 and 2, Scheme 1) and/or with D-galactose branches along the glycan core (nonstoichiometric, not shown). As the issues regarding the structural features responsible for the activity can only be resolved through synthesis, a multidisciplinary program has been launched in our laboratory aimed at the chemical preparation of various T. cruzi trypomastigote mucin GPIs (including those containing D-galactose branches) and the meticulous elucidation of their structure-activity relationships. Herein, we report the first chemical syntheses of tGPIs from T. cruzi bearing oleic (compound 1) and linoleic (compound 2) acid moieties.

There are two major structural features that make compounds **1** and **2** different from the GPIs synthesized previously:^[4-10] 1) the presence of unsaturated fatty acids in the lipid moiety instead of saturated ones; and 2) the presence of 2-aminoethylphosphonate at the O6 position of the D-glucosamine moiety, which is a parasite-specific substituent

^[*] The content of fatty acid components in the biologically active tGPI anchor fraction was: oleic acid, C18:1, 31%; linoleic acid, C18:2, 21%; and palmitic acid, C16:0, 37%.^[13]



Scheme 1. Retrosynthetic scheme showing key building blocks and D-mannose monosaccharide intermediates. Boc = tert-butoxycarbonyl, Bz = benzoyl, SEM = 2-trimethylsilylethoxymethyl, TBS = tert-butyldimethylsilyl, $TCA = C(NH)CCl_3$, trichloroacetimidyl, TES = triethylsilyl.

for *T. cruzi* only. As the presence of double bonds was not compatible with the use of benzyl ethers (widely used before^[4-10]) as permanent O-protecting groups, a novel strategy was developed which implied exploration of benzoic esters and acid-labile (acetals and *N*-Boc) groups for O,N protection. Various silyl ethers were employed as orthogonal blocking groups for the O6 of D-glucosamine (TES), O6 of D-mannose-3 (primary TBS), and O1 of *myo*-inositol (secondary TBS) to ensure further introduction of the P-containing esters. For the final deprotection, we expected that mild basic treatment in polar solvent would preferentially cleave the benzoates and leave the fatty ester of the lipid mostly intact because of micelle formation.


By following the retrosynthetic disconnection shown in Scheme 1, the GPIs 1 and 2 were assembled from the mannotetraose building block 5, the azidoglucose-inositol block 6, and P-containing derivatives phosphonodichloridate 3 and the hydrogenphosphonates 4 and 7 (or 8), which were used for consecutive introduction of the 2-aminoethylphosphonate, ethanolamine phosphate, and acylalkylglycerophosphate fragments, respectively.

The tetrasaccharide block **5** was prepared from the monosaccharide derivatives **9–12**, which were assembled in a step-by-step manner (Scheme 2). Compounds **9** and **12**, in turn, were synthesized from p-mannose as well as the


derivatives 10 and 11, which progressed via the common 3,4,6-tri-O-acetyl-1,2-O-(1-methoxyethyliintermediate dene)-β-D-mannose.^[16] The disaccharide **13** (94%) was prepared first by coupling of the glycosyl acceptor 12 and the trichloroacetimidate 11 in the presence of trimethylsilyl triflate (TMSOTf). It was then deacetylated^[17] with HCl in MeOH (\rightarrow 14) followed by reaction with glycosyl donor 10 and TMSOTf to produce the trisaccharide 15 (96%). Subsequent deacetylation $(\rightarrow 16)$ and one more glycosylation with the trichloroacetimidate 9 and TMSOTf provided the tetrasaccharide 17 (99%). The α configuration of the newly created D-mannoside bonds was secured by the structure of mannosyl donors 9-11, which contained participating protecting groups at the O2 position. Compound 17 was then converted to the mannotetraose glycosyl donor 5 (66% yield) by consecutive reprotection at the O6" position (hydrogenation over Pd catalyst followed by silvlation with TBSOTf/ Et₃N; \rightarrow **18**), anomeric debenzoylation with ethylenediamine, and reaction with CCl₃CN in the presence of Cs₂CO₃.

The azidoglucose–inositol block **6** was synthesized (Scheme 3) from the pseudo-disaccharide **23**, which was described by Schmidt and co-workers^[4,18] as a glycosylation product of the optically pure D-*myo*-inositol derivative **21**^[19] with the azidoglucose trichloroacetimidate **19**. We found that the resolution of diastereomeric (–)-menthyloxycarbonyl-

Communications



Scheme 2. Reagents: a) TMSOSO₂CF₃, CH₂Cl₂; b) 2% HCl, MeOH/CH₂Cl₂; c) H₂, Pd(OH)₂/C, THF; d) TBSOSO₂CF₃, Et₃N, CH₂Cl₂; e) NH₂CH₂CH₂NH₂·HOAc, THF; f) CCl₃CN, Cs₂CO₃, CH₂Cl₂. Bn = benzyl, THF = tetrahydrofuran, TMS = trimethylsilyl.




Scheme 3. Reagents: a) TMSOSO₂CF₃, MS4A, Et₂O/CH₂Cl₂; b) 0.02 \mbox{M} NaOMe, MeOH/CH₂Cl₂; c) PhC(OEt)₃, CSA, CH₂Cl₂; d) SEMCl, *i*Pr₂NEt, CH₂Cl₂; e) 1 \mbox{M} NaOMe, MeOH/CH₂Cl₂; f) TBSOSO₂CF₃, Et₃N, CH₂Cl₂; g) CH₂Cl₂/CF₃COOH/water (1000:1:0.1); h) 0.1 \mbox{M} NaOMe, MeOH/CH₂Cl₂; i) TESCl, pyridine, CH₂Cl₂, -20 °C. CSA = camphor-10-sulfonic acid, Mnt = menthyl, MS4A = 4.Å molecular sieves.

myo-inositols **21** (D product) and **20** (L product) could be avoided, but it was possible to perform glycosylation of the whole mixture and then isolate the required derivative **23** by standard flash column chromatography on SiO₂. Coupling of the mixture **21** + **20** (7:3, according to ¹H NMR data; prepared as described in reference [19]) with the glycosyl

donor $19^{[20]}$ in the presence of TMSOTf and 4-Å molecular sieves proceeded smoothly and gave the easily separable ($R_{\rm f}$ difference of 0.1) diastereomers 23 and 22, which were isolated in 64 and 30% yield, respectively (that is, 94% total yield of the glycosylation based on the mixture 21 + 20). Both compounds had an α configuration of the D-glucoside bond, which was confirmed by the characteristic values (3.5 Hz for **23** and 3.6 Hz for **22**) for $J_{1',2'}$ coupling constants. Clearly, the 2-azido-2-glucose- α -D-glucosyl moiety worked as an additional powerful chiral auxiliary and facilitated the separation of D- and L-*myo*-inositol derivatives.

For the transformation $23 \rightarrow 6$, first, the introduction of the acid-labile 2-trimethylsilylethoxymethyl (SEM) permanent protecting group at the O3' position was needed. This was performed through the mild basic deacetylation of 23 followed by orthoesterification with PhC(OEt)₃ in mild acidic conditions (to form the 4',6'-orthoester derivative 24) and reaction with SEM chloride in the presence of N,Ndiisopropylethylamine. Basic cleavage of the (-)-menthylcarbonate gave the 1-hydroxy derivative 25, which was then successively silvlated with TBSOTf/Et₃N, hydrolyzed with 0.1% trifluoroacetic acid (TFA)/water in CH₂Cl₂ (10 min) to open the orthoester (thus forming a mixture of 4'- and 6'acetates), deacetylated (with MeONa in MeOH; \rightarrow 26), and silvlated at the O6' position with Et₃SiCl in pyridine/CH₂Cl₂. Thus, the azidoglucose-inositol block 6 was prepared from compound 23 in seven steps in approximately 50% overall vield.

The 2-azidoethylphosphonodichloridate **3** was prepared (Scheme 4) from diethyl 2-bromoethylphosphonate **27** through the azidation reaction with NaN₃ (\rightarrow **28**) followed by de-esterification with Me₃SiBr and chlorination with oxalyl chloride in the presence of *N*,*N*-dimethylformamide. The 2-(*N*-Boc)-aminoethyl hydrogenphosphonate **4** was prepared by the reaction of *N*-Boc-ethanolamine **29** with H₃PO₃ in the presence of pivaloyl chloride.^[21] The 2-*O*-acyl-1-*O*-hexadecyl-



7 and 32 R = $(CH_2)_7CH=CH(CH_2)_7CH_3$ 8 and 33 R = $(CH_2)_7CH=CHCH_2CH=CH(CH_2)_4CH_3$

Scheme 4. Reagents: a) NaN₃, nBu₄NHSO₄ cat., toluene; b) TMSBr, MeCN; c) (COCl)₂, DMF cat., CH₂Cl₂; d) H₃PO₃, pivaloyl chloride, pyridine; e) CH₃(CH₂)₁₅I, NaH, DMF/THF; f) CF₃COOH/water (9:1);
g) TESCI, pyridine, CH₂Cl₂; h) oleoyl chloride for 32 (or linoleoyl chloride for 33), Et₃N, DMAP, pyridine; i) 3HF·Et₃N, MeCN/CH₂Cl₂;
j) trijmidazolylphosphine, MeCN/CH₂Cl₂; k) Et₃NHHCO, water (pH 7). DMAP = 4-dimethylaminopyridine, DMF=N,N-dimethylformamide.

sn-glyceryl hydrogenphosphonates **7** and **8** were synthesized starting from commercially available 2,3-*O*-isopropylidene*sn*-glycerol **30**, which was first alkylated with *n*-hexadecyl iodide in the presence of NaH followed by acid hydrolysis to produce 1-*O*-hexadecyl-*sn*-glycerol **31** (55%). This compound was then successively silylated at the 3-hydroxy group with Et₃SiCl in pyridine, esterified with oleoyl or linoleoyl chloride, and desilylated with 3HF·Et₃N, thus providing the 2-*O*-acylated glycerol derivatives **32** and **33**, respectively. Each of them was converted (almost quantitatively) to the corresponding hydrogenphosphonate derivative (**7** and **8**, respectively) by reaction with triimidazolylphosphine^[22] followed by hydrolysis.


With all the principal building blocks in hand, we pursued the preparation of the target GPIs 1 and 2. First, the glycaninositol backbone 34 was prepared (Scheme 5) by the glycosylation of the glycosyl acceptor 6 with the mannotetraose trichloroacetimidate 5 in the presence of TMSOTf and 4-Å molecular sieves. Subsequent cleavage of the TES group (the "weakest" of the three silvl protecting groups) with acetic tetrabutylammonium acid-buffered fluoride (TBAF) smoothly gave the 6'-hydroxy pseudo-hexasaccharide derivative 35 (60% from 5), ready to turn to the "P-decoration" procedures. 1H-Tetrazole-assisted esterification of 35 with the phosphonodichloridate 3 followed by methanolysis afforded the phosphonic diester 36 (79%) as a diastereomeric mixture^[*] ($\delta_{\rm P} = 28.5, 28.8$). It was then a subject of successive reduction of the azido groups with Ph₃P, N protection with Boc anhydride (\rightarrow 37), and selective cleavage of the primary TBS ether with 3HF·Et₃N, thus cleanly producing the 6^{''''}-

hydroxv glycan-inositol-phosphonate compound 38 (80%). Furthermore, the introduction of the ethanolamine phosphate moiety was performed by the condensation of 38 with the hydrogenphosphonate derivative 4 (activated by pivaloyl chloride)^[23] followed by in situ oxidation with iodine in aqueous pyridine. The phosphonate-phosphate block 39 was isolated in 88% yield prior to the final desilvlation with TBAF/AcOH (at 55°C), which gave the 1-hydroxy glycoconjugated derivative 40.

We reported earlier^[24] that the presence of phosphodiester units in a molecule still allows the next O-phosphorylation step to be performed effectively by the hydrogenphosphonate method (that is, P protection for phosphodiesters is not required). Indeed, compound **40** (containing a phosphodiester moiety at the O6'''' position) was successfully phospholipi-

^[*] The P protection was required at this stage to avoid undesired modifications of the phosphonate moiety during further transformations. Each of the methyl phosphonate derivatives 36-42 was formed as a mixture of diastereomers at the phosphorus atom (in a ratio of 1:1), as clearly indicated by the ³¹P NMR spectra (see Supporting Information).

Communications



Scheme 5. Reagents: a) TMSOSO₂CF₃, MS4A, CH₂Cl₂; b) nBu_4NF , AcOH, THF (20°C, 1.5 h); c) 1*H*-tetrazole, *i*Pr₂NEt, toluene; d) MeOH; e) Ph₃P, water, THF; f) Boc₂O, Et₃N, MeOH; g) 3HF·Et₃N, MeCN/THF; h) pivaloyl chloride, pyridine; i) I₂, pyridine/water; j) nBu_4NF , AcOH, THF (55 °C, 60 h).

dated (Scheme 6) by a pivaloyl chloride assisted reaction with the acylalkylglyceryl hydrogenphosphonate **7**, followed by in situ oxidation with iodine to provide the fully protected oleic ester GPI **41** in 95% yield. Similarly, the protected linoleic ester GPI **42** (85%) was prepared from **40** and the hydrogenphosphonate **8**. Both compounds **41** and **42** were immediately demethylated at the aminoethylphosphonate moiety with PhSH/Et₃N^[25] to form GPI derivatives **43** and **44**, respectively.

Global deprotection of **43** was performed in two steps. First, controlled O-debenzoylation with 0.05 M methanolic sodium methoxide (3 h) gave the partly protected GPI **45**, which was isolated in 40 % yield by flash column chromatography on SiO₂. The presence of the fatty ester in the molecule was clearly indicated by MALDI-TOF mass spectrometry (MS) data.^[26] Subsequent cleavage of *O*-acetal and *N*-Boc protecting groups with aqueous 90% TFA followed by purification by reversed-phase chromatography (on a C4 silica column with gradient elution with propan-1-ol/ water/TFA, 10:90:0.05 \rightarrow 95:5:0.05) provided the targeted oleic ester GPI **1**. The protected derivative **44** was converted to the linoleic ester GPI **2** in a similar manner.

The structures of the glycosylphospholipids **1** and **2** were supported by NMR spectroscopy and MS data. The ¹H, ¹³C, and ³¹P NMR spectra for **1** were almost identical to those for **2**. Full structural assignment of **2** was performed by a combination of ¹H and ¹³C NMR, COSY, ROESY, TOCSY, and heteronuclear single-quantum correlation (HSQC) spectroscopy (see Table 1). The ³¹P NMR signals were assigned with the ¹H,³¹P heteronuclear multiple-quantum correlation (HMQC) technique. The molecular masses for the GPIs **1** and **2** were confirmed by MALDI-TOF and electrospray (ES) MS.^[26]

The synthetic GPIs **1** and **2** revealed biological activity: preliminary experiments using Toll-like receptor (TLR) transfected Chinese hamster ovary (CHO) cell lines showed they stimulated TLR2-transfected cells and not TLR4-transfected cells,^[27] like naturally occurring tGPI.^[28] A detailed biological evaluation of the compounds is currently in progress and will be published elsewhere in due course.

In summary, a novel approach for the chemical synthesis of glycosylphosphatidylinositols, which exploits the use of non-benzyl-type protecting groups, was designed. The method showed its utility in the first syntheses of *T. cruzi* trypomastigote GPIs containing unsaturated fatty acids in the lipid moiety.

Received: August 5, 2005 Revised: October 3, 2005 Published online: December 8, 2005


Table 1: Correlation table of **2**: ¹H, ¹³C NMR and ³¹P chemical shifts at 500, 125, and 202 MHz, respectively. Measurements in [D₆]DMSO at 30 °C; δ values [ppm] are given relative to Me₄Si (for ¹H and ¹³C) and external aqueous 85% H₃PO₄ (for ³¹P).

Residue ^[a]	Atom						
	H1	H2	H3	H4	H5	H6	Р
	C1	C2	C3	C4	C5	C6	
Ino ^[b]	4.03	3.81	3.48	3.46	3.16	3.75	-0.6
	75.7	70.45	73.65	72.65	73.1	78.5	
GlcNH ₂ ^[c]	5.48	2.96	3.82	3.49	4.27	4.07 + 3.94	18.7
	94.3	53.8	70.1	76.25	69.2	63.1	
Man-1	5.11	3.86	3.48	3.60	3.19	3.85 + 3.62	
	101.25	71.8	70.65	66.1	70.8	65.6	
Man-2	4.85	3.78	3.70	3.45	3.62	3.67 + 3.42	
	98.2	77.05	70.1	67.1	72.4	61.2	
Man-3 ^[d]	5.08	3.88	3.61	3.39	3.37	4.10 + 3.75	-1.5
	100.9	77.05	69.9	67.1	70.6	65.4	
Man-4	4.86	3.80	3.75	3.71	3.30	3.68 + 3.49	
	101.85	71.8	69.9	66.6	71.8	60.9	

[a] Important inter-residue correlation peaks in the ROESY spectrum: H1 (GlcNH₂)/H6 (Ino); H1 (GlcNH₂)/H1,5 (Ino); H1 (Man-1)/H4 (GlcNH₂); H1 (Man-2)/H6,6' (Man-1); H1 (Man-3)/H2 (Man-2); H1 (Man-4)/H2 (Man-3). Important correlation peaks in the ¹H,³¹P HMQC spectrum: P^I (δ_p = 18.7 ppm) with H6,6' (GlcNH₂) and P-CH₂-CH₂-NH₃⁺; P^{III} (δ_p = -0.6 ppm) with H1 (Ino) and H3 (glycerol); P^{III} (δ_p = -1.5 ppm) with H6,6' (Man-3) and P-O-CH₂-CH₂-NH₃⁺. [b] Additional signals of glycerol were present: CH₂-O-P, $\delta_{\rm H}$ = 3.80 ppm, $\delta_{\rm C}$ = 63.1 ppm; CH-O-acyl, $\delta_{\rm H}$ = 5.02 ppm, $\delta_{\rm C}$ = 71.0 ppm; CH₂-O-alkyl, $\delta_{\rm H}$ = 3.52 and 3.47 ppm, $\delta_{\rm C}$ = 68.9 ppm. [c] Additional signals of the aminoethyl-phosphonate P-CH₂-CH₂-NH₃⁺ were present: PCH₂, $\delta_{\rm H}$ = 2.01 ppm, $\delta_{\rm C}$ = 26.5 ppm; NCH₂, $\delta_{\rm H}$ = 3.06 and 3.00 ppm, $\delta_{\rm C}$ = 65.7 ppm; NCH₂, $\delta_{\rm H}$ = 3.06 and 3.00 ppm, $\delta_{\rm C}$ = 65.7 ppm; NCH₂, $\delta_{\rm H}$ = 3.06 and 3.00 ppm.

Keywords: carbohydrates · glycosides · phospholipids · protozoa · synthetic methods

- a) M. A. J. Ferguson, S. W. Homans, R. A. Dwek, T. W. Rademacher, *Science* **1988**, *239*, 753; b) S. W. Homans, M. A. J. Ferguson, R. A. Dwek, T. W. Rademacher, R. Anand, A. F. Williams, *Nature* **1988**, *333*, 269.
- [2] a) M. J. McConville, M. A. J. Ferguson, *Biochem. J.* 1993, 294, 305; b) M. J. McConville, A. K. Menon, *Mol. Membr. Biol.* 2000, 17, 1.
- [3] a) K. G. Rothberg, J. E. Heuser, W. C. Donzell, Y.-S. Ying, J. R. Glenney, G. W. Anderson, *Cell* **1992**, *68*, 673; b) R. Varma, S. Mayor, *Nature* **1998**, *394*, 798; c) H.-H. Caro, M. Martin-Lomas, M. Bernabe, *Carbohydr. Res.* **1993**, *240*, 119.
- [4] a) T. G. Mayer, B. Kratzer, R. R. Schmidt, Angew. Chem. 1994, 33, 2289; Angew. Chem. Int. Ed. Engl. 1994, 33, 2177; b) T. G. Mayer, R. R. Schmidt, Eur. J. Org. Chem. 1999, 1153.
- [5] a) A. S. Campbell, B. Fraser-Reid, J. Am. Chem. Soc. 1995, 117, 10387; b) K. Pekari, R. R. Schmidt, J. Org. Chem. 2003, 68, 1295.
- [6] D. K. Baeschlin, A. R. Chaperon, L. G. Green, M. E. Hahn, S. J. Ince, S. V. Ley, *Chem. Eur. J.* **2000**, *6*, 172.
- [7] K. Ruda, J. Lindberg, P. J. Garegg, S. Oscarson, P. Konradsson, J. Am. Chem. Soc. 2000, 122, 11067.
- [8] K. Pekari, D. Tailler, R. Weingart, R. R. Schmidt, J. Org. Chem. 2001, 66, 7432.
- [9] J. Lu, K. N. Jayaprakash, U. Schlueter, B. Fraser-Reid, J. Am. Chem. Soc. 2004, 126, 7540.
- [10] A. Ali, D. C. Gowda, R. A. Vishwakarma, Chem. Commun. 2005, 519.



Scheme 6. Reagents: a) pivaloyl chloride, pyridine; b) I₂, pyridine/water; c) PhSH, Et₃N, DMF; d) 0.05 м NaOMe, MeOH; e) CF₃COOH/water (9:1).

Angew. Chem. Int. Ed. 2006, 45, 468–474

© 2006 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim

Communications

- [11] D. H. Molyneux in *Trypanosomiasis and Leishmaniasis* (Ed.: G. Hide et al.), CAB International, Wallingford, UK, **1997**, pp. 39– 50.
- [12] M. L. S. Güther, M. L. Cardoso de Almeida, N. Yoshida, M. A. J. Ferguson, J. Biol. Chem. 1992, 267, 6820.
- [13] I. C. Almeida, M. M. Camargo, D. O. Procopio, L. S. Silva, A. Mehlert, L. R. Travassos, R. T. Gazzinelli, M. A. J. Ferguson, *EMBO J.* 2000, *19*, 1476.
- [14] V. L. Pereira-Chioccola, A. Acosta-Serrano, I. Correia de Almeida, M. A. J. Ferguson, T. Souto-Padron, M. M. Rodrigues, L. R. Travassos, S. Schenkman, J. Cell Sci. 2000, 113, 1299.
- [15] I. C. Almeida, R. T. Gazzinelli, J. Leukocyte Biol. 2001, 70, 467.
 [16] P. Dais, T. K. M. Shing, A. S. Perlin, Carbohydr. Res. 1983, 122, 305.
- [17] N. E. Byramova, M. V. Ovchinnikov, L. V. Backinowsky, N. K. Kochetkov, *Carbohydr. Res.* **1983**, *124*, c8.
- [18] B. Kratzer, T. G. Mayer, R. R. Schmidt, Eur. J. Org. Chem. 1998, 291.
- [19] T. G. Mayer, R. R. Schmidt, Liebigs Ann. 1997, 859.
- [20] G. Grundler, R. R. Schmidt, Liebigs Ann. Chem. 1984, 1826.
- [21] C. Lin, H. Fu, G. Tu, Y. Zhao, Synthesis 2004, 509.
- [22] I. Lindh, J. Stawinski, J. Org. Chem. 1989, 54, 1338.
- [23] J. Stawinski, R. Strömberg, Trends Org. Chem. 1993, 4, 31.
- [24] A. V. Nikolaev, T. J. Rutherford, M. A. J. Ferguson, J. S. Brima-
- combe, J. Chem. Soc. Perkin Trans. 1 1996, 1559.
 [25] B. Muller, T. J. Martin, C. Schaub, R. R. Schmidt, *Tetrahedron Lett.* 1998, 39, 509.
- [26] MS data for 1, $C_{77}H_{146}N_3O_{41}P_3$ (1861.86): MALDI-TOF MS (negative mode, matrix: 2,5-dihydroxybenzoic acid): m/z 1861.09 $[M-H]^-$; ES-TOF MS (positive mode): m/z 931.94 $[M+2H]^{2+}$; ES MS (negative mode): m/z 930.0 $[M-2H]^{2-}$, 941.0 $[M-3H+Na]^{2-}$, 1861.0 $[M-H]^{-}$. MS data for 2, $C_{77}H_{144}N_3O_{41}P_3$ (1859.85): MALDI-TOF MS (positive mode, matrix: 2,5-dihydroxybenzoic acid): m/z1923.00 $[M-H+2Na+NH_3]^+$; ES MS (positive mode): m/z 1240.50 $[2M+3H]^{3+}$, 1791.90 $[M-NH_2C_2H_4PO_2H+H+Na+NH_3]^+$, 1847.70 [M-NH₂C₂H₄PO₂H+Na+K+2NH₃]⁺. MS data for 45 (H⁺ form), C₁₁₀H₂₀₀N₃O₄₈P₃Si (2452.23): MALDI-TOF MS (negative mode, matrix: 2,5-dihydroxybenzoic acid): m/z 2451.45 $[M - H]^{-}$.
- [27] I. C. Almeida, unpublished results.
- [28] M. A. S. Campos, I. C. Almeida, O. Takeuchi, S. Akira, E. P. Valente, D. O. Procopio, L. R. Travassos, J. A. Smith, D. T. Golenbock, R. T. Gazzinelli, *J. Immunol.* **2001**, *167*, 416.